He built a MERS treat­ment in 6 months and then the best Ebo­la drug. Now Chris­tos Kyrat­sous turns his sights on Covid-19

9 hours ago
R&D

FDA goes on high alert as coro­n­avirus rais­es threat to drug man­u­fac­tur­ing and clin­i­cal tri­als grind to a halt

11 hours ago
R&D
Regulatory

War­ren Buf­fett gets a dou­ble take as the in­vest­ment pow­er­house set­tles on its first biotech in­vest­ment

13 hours ago
R&D

Palleon's first CSO ex­plains how they (and she) got here; En­ter­prise taps Roche and No­var­tis vet David Mor­ris as CMO

4 days ago
Peer Review

New en­tries, price hikes spur changes among the 20 most ex­pen­sive drugs — though not the kind politi­cians like to see

4 days ago
Pharma

Coro­n­avirus out­break clouds As­traZeneca's Q4 re­sults and 2020 out­look

4 days ago
Pharma
R&D

The list of the 11 block­busters-to-be in line for a 2020 launch high­light agony and ec­sta­sy of drug R&D

4 days ago
Pharma

8 years af­ter its OK, Ei­sai yanks its flail­ing obe­si­ty drug from the mar­ket af­ter FDA flagged high­er can­cer rate

5 days ago
Pharma
Regulatory

Af­ter FDA hold and tri­al fail­ure, Ipsen writes down its big ac­qui­si­tion — but they're not giv­ing up

5 days ago
Pharma

The RAS rush: Rev­o­lu­tion Med­i­cines bags re­mark­able $238M IPO raise, more than dou­bling orig­i­nal goal

5 days ago
IPOs

Coro­n­avirus up­date: A sum­mit in Gene­va, WuXi hunts an­ti­bod­ies and J&J part­ners on a vac­cine search

6 days ago
R&D

Corey Good­man mar­shals $105M mega-round for his CD47 up­start, look­ing to break new ground in PhII

6 days ago
R&D
Startups

New Sanofi chief Paul Hud­son takes the ax to his ex­ec­u­tive com­mit­tee, chop­ping 4 key play­ers

6 days ago
R&D

Bay­er hands over a big drug R&D op­er­a­tion to CRO amid an on­go­ing re­struc­tur­ing ef­fort

6 days ago
Deals
R&D

Agios' Lewis Cant­ley re­turns with a new com­pa­ny and, he claims, a ma­jor on­co­log­i­cal dis­cov­ery

Last week
R&D

Up­start can­cer biotech re­cruits a top Pfiz­er on­col­o­gy re­searcher as CSO — could an IPO be far be­hind?

Last week
R&D

Mer­ck-al­lied Seat­tle Ge­net­ics’ pos­i­tive up­date on its 2nd ADC may point to an ac­cel­er­at­ed dash to the FDA fin­ish line

Last week
R&D

Mer­ck walks away from KalVista, who turns their sights on HAE

Last week
Deals

With block­buster dreams, Ex­elix­is is look­ing for some re­demp­tion for cabo in prostate can­cer. It won’t be easy

Last week
Pharma
R&D

Vivek Ra­maswamy's Ar­bu­tus kills an­oth­er pro­gram over safe­ty, stock takes an­oth­er hit

Last week
R&D

Bio­haven's re­for­mu­lat­ed ALS drug is a flop in anx­i­ety, un­nerv­ing in­vestors ahead of CGRP mi­graine de­ci­sion

Last week
R&D

FDA hands Gilead a nice CAR-T boost as crit­ics pounce on un­der­whelm­ing Q4 call and Twit­ter buzzes with M&A chat­ter

Last week
R&D

Fo­cus­ing on ge­net­i­cal­ly de­fined pop­u­la­tion still could­n't save Eli Lil­ly, Roche's an­ti-amy­loid Alzheimer's drugs

Last week
R&D

A crash­ing Wave takes out the bud­get ax to chop staff, aban­don­ing work on Duchenne MD in re­struc­tur­ing

Last week
People
R&D
1234 Next page Last page